However, no study has exclusively evaluated the effectiveness and tolerability of the PD-1 immunotherapy camrelizumab combined with molecular targeted therapy such as sorafenib, lenvatinib, and apatinib in patients with advanced HCC with Child-Pugh B liver function in the real world. Here, PDCD1 is linked to hepatocellular carcinoma.